Legal Opinion
In re Cell Pathways, Inc., Securities Litigation II
District Court, E.D. Pennsylvania
Decided July 27, 2001No. 01-CV-1189PublishedCited by 1 opinion
1Opinion of the Court
MEMORANDUM AND ORDER
MCLAUGHLIN, District Judge.
These consolidated actions brought against Cell Pathways, Inc. (“Cell Pathways”), Robert Towarnicki, and Rifat Pamukcu seek damages for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and Rule 10b-5 promulgated thereunder. They are brought on behalf of purchasers of Cell Pathways securities between October 27, 1999 and September 22, 2000, and allege that the defendants made false and misleading statements concerning the drug Aptosyn.
The Court must now decide two competing motions for appointment…
2Cases cited7 opinions
- 9 Fair empl.prac.cas. 211, 9 Empl. Prac. Dec. P 9931 Sandra Wetzel and Mari Ross, on Behalf of Themselves and All Others Similarly Situated, Equal Opportunity Commission as Amicus Curiae v. Liberty Mutual Insurance Company, a CorporationCourt of Appeals for the Third Circuit · 1975
- Gluck v. CellStar Corp.District Court, N.D. Texas · 1997
- Chill v. Green Tree Financial Corp.District Court, D. Minnesota · 1998
- In Re Razorfish, Inc. Securities LitigationDistrict Court, S.D. New York · 2001
- In Re Microstrategy Inc. Securities LitigationDistrict Court, E.D. Virginia · 2000
2 more not listed; retrieve them via the Exa API.
3Cited by1 opinion
- In re Vicuron Pharmaceuticals, Inc. Securities LitigationDistrict Court, E.D. Pennsylvania · 2004